Loading
A phase 2 trial of Enzalutamide, Abiraterone acetate, Prednisone in prostate cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study is a phase 2 interventional study registered as NCT02960022 by Astellas Pharma Global Development, Inc., with 900 participants planned, started 2016-12-22 and due to reach its primary completion in 2029-07-31. Interventions recorded: enzalutamide, abiraterone acetate, prednisone, Leuprolide acetate. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Astellas, Abiraterone acetate, Prednisone, Prostate cancer.
Shares Astellas, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Prednisone, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/